Fenebrutinib Clears Phase III Bar, NDA Filing Now in Sight for RMS and PPMS

Roche is moving toward a regulatory submission for fenebrutinib across two multiple sclerosis indications after Phase III FENhance 1 and 2 studies met their primary endpoints, reducing annualised relapse rates (ARR) by 51.1% and 58.5% respectively versus teriflunomide over 96 weeks. For QA directors and regulatory affairs leads already tracking the BTK inhibitor class, the data package now spans three pivotal studies covering both relapsing MS (RMS) and primary progressive MS (PPMS), a breadth that will shape the filing strategy and, downstream, the manufacturing scale-up requirements for what could become the first high-efficacy oral agent approved across both disease subtypes.

The FENhance results, presented as a late-breaking session at the 2026 American Academy of Neurology Annual Meeting in Chicago, translate the ARR reductions into a clinically tangible figure: approximately one relapse every 17 years for patients on fenebrutinib, compared with roughly one every eight years on teriflunomide. Secondary MRI endpoints reinforced the primary outcome. New T1 gadolinium-enhancing lesions -- a direct marker of active inflammation -- were reduced by 70.7% in FENhance 1 and 77.6% in FENhance 2 versus teriflunomide. New or enlarging T2 lesions, reflecting chronic disease burden, fell by 76.0% and 82.5% in the respective studies. Disability progression trended in favour of fenebrutinib: composite confirmed disability progression at 12 weeks (cCDP12) showed a 20% numerical risk reduction (HR 0.80; 95% CI: 0.63-1.02) in FENhance 1 and 13% (HR 0.87; 95% CI: 0.69-1.11) in FENhance 2, though confidence intervals crossed unity in both cases, meaning statistical significance was not achieved on this endpoint.

Subgroup and safety signals carry operational weight. Relapse reductions were consistent across patient subgroups, with the largest effects observed in patients with active brain lesions, younger age, more recent diagnosis, and lower baseline disability -- characteristics that will inform label negotiations with regulators. On the hepatic safety front, liver enzyme elevations were reported at comparable rates to teriflunomide, a finding that will factor into pharmacovigilance planning and the risk management strategy embedded in any NDA or MAA submission. Fenebrutinib's non-covalent mechanism of BTK inhibition distinguishes it from earlier covalent agents in the class, a differentiation point that regulatory teams will need to address in the benefit-risk narrative.

Jiwon Oh, M.D., Ph.D., Medical Director of the Barlo Multiple Sclerosis Program at St. Michael's Hospital, University of Toronto, noted that fenebrutinib is the first BTK inhibitor to demonstrate superiority in reducing relapses and new brain lesion formation versus a first-line standard of care across multiple Phase III RMS trials. Roche Chief Medical Officer Levi Garraway, M.D., Ph.D., confirmed that the totality of RMS and PPMS data will be submitted to regulatory authorities, signalling that a combined filing strategy is the current intent rather than a sequenced indication-by-indication approach.

For plant heads and manufacturing leads, the oral solid dose format of fenebrutinib -- if the filing proceeds and approval follows -- will require process validation packages aligned with ICH Q10 and 21 CFR Part 211 expectations for a high-efficacy agent with a novel mechanism. Roche has not disclosed a submission timeline, but the confirmed intent to file across both indications simultaneously suggests regulatory and CMC teams are already in active preparation. Pharma Now will continue to track the submission and any agency feedback as it becomes available.